Skip to main content
. Author manuscript; available in PMC: 2010 Sep 18.
Published in final edited form as: Vaccine. 2009 Aug 3;27(41):5554–5561. doi: 10.1016/j.vaccine.2009.07.034

Fig. 3.

Fig. 3

Intranasal immunization with KKF 235 protected mice against homotypic F. novicida challenge. BALB/c mice received a single immunizing dose (106 CFU) of KKF235 or PBS (as a mock control). Mice were rested for 30 days, then challenged i.n. with 1000 CFU of U112 (∼100 LD50). Mice were monitored for survival (A). Difference in survival between KKF235- and mock- vaccinated mice was significant at a p<0.005. Sera (B) were collected at 14 and 28 days, and BAL fluid (C) collected at 28 days after immunization and used to determine the levels of anti-KKF235 specific antibody. Differences in antibody binding in the sera between between KKF235- and mock-vaccinated mice (titer < 100; data not shown) were significant at a p value of <0.01. Differences in antibody binding between KKF235- and mock-vaccinated mice were significant at a p value of <0.0001 for Total Ab, IgG1 and IgG2a, <0.005 for IgA, and <0.0005 for IgM in the BAL.